3,3′-diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4468-4475

  Rahman, K M Wahidur ^a   Banerjee, Sanjeev ^a   Ali, Shadan ^a   Ahmad, Aamir ^a   Wang, Zhiwei ^a   Kong, Dejuan ^a   Sakr, Wael A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; DOCETAXEL; SMALL INTERFERING RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; DIINDOLYLMETHANE; INDOLE DERIVATIVE; LUCIFERASE; MICROTUBULE ASSOCIATED PROTEIN; TAXOID;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA TRANSFECTION; DOWN REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BONE TUMOR; BREAST TUMOR; CELL DIVISION; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PLASMID; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; LUCIFERASES; MALE; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS; PLASMIDS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 66249136410     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4423     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Bracarda S, de Cobelli O, Greco C, et al. Cancer of the prostate. Crit Rev Oncol Hematol 2005;56:379-96.
3. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-19.
4. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
5. Ghosh PM, Malik SN, Bedolla RG, et al. Signal transduction pathways in androgen-dependent and - independent prostate cancer cell proliferation. Endocr Relat Cancer 2005;12:119-34.
6. Kokontis JM, Hsu S, Chuu CP, et al. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 2005;65:287-98.
7. Schulze H, Isaacs J, Senge T. Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. J Urol 1987;137:909-11.
8. Gunawardena K, Campbell LD, Meikle AW. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells. Cancer Detect Prev 2005;29:389-95.
9. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005;24:2474-82.
10. Li Y, Che M, Bhagat S, et al. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 2004;6:354-63.
11. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006; 66:4952-60.
12. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004; 171:1855-60.
13. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-25.
14. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007;67:8014-21.
15. Zhang SQ, Qiang SY, Yang WB, Jiang JT, Ji ZZ. Expression of survivin in different stages of carcinogenesis and progression of breast cancer. Ai Zheng 2004;23: 697-700.
16. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000;46:645-50.
17. Monzo M, Rosell R, Felip E, et al. A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4.
18. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
19. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000-5.
20. Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 2008;72:1229-33.
21. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004;100:751-7.
22. Wu J, Ling X, Pan D, et al. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem 2005;280:9745-51.
23. 34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230-5.
24. Xia W, Bisi J, Strum J, et al. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 2006;66: 1640-7.
25. Garikapaty VP, Ashok BT, Tadi K, Mittelman A, Tiwari RK. 3,3′-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun 2006;340:718-25.
26. Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-κB by 3,3′-diindolylmethane (DIM) contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007;6:1-9.
27. Rahman KM, Sarkar FH. Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 2005;65:364-71.
28. kip. Mol Cancer Ther 2008;7:341-9.
29. Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001;57:122-6.
30. Oh WK, George DJ, Kaufman DS, et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001;28:40-4.
31. Li B, Sun A, Youn H, et al. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 2007;28:572-83.
32. Kikuchi E, Horiguchi Y, Nakashima J, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 2003;63:107-10.
33. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89:40-8.
34. McMurtry CT, McMurtry JM. Metastatic prostate cancer: complications and treatment. J Am Geriatr Soc 2003;51:1136-42.
35. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB. Assay for redox-sensitive transcription factor. Methods Enzymol 2000;319:585-602.
36. Rahman KM, Li Y, Sarkar FH. Inactivation of Akt and NF-κB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer 2004;48:84-94.
37. Nemeth JA, Harb JF, Barroso U, Jr., He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-93.
38. Rahman KM, Sarkar FH, Banerjee S, et al. Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther 2006;5: 2747-56.
39. Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and Taxotere combination in prostate cancer. Cancer Res 2007;67:3818-26.
40. Shakuto S, Fujita F, Fujita M. Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice. Gan To Kagaku Ryoho 2006;33:337-43.
41. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003;63:1059-66.
42. Thomas S, Shah G. Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther 2005;4:1226-33.
43. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008;173:575-85.
44. 1-S cell cycle progression of T lymphocytes. Nat Immunol 2007;8:64-73.
45. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005;4:1201-15.
46. Hong C, Kim HA, Firestone GL, Bjeldanes LF. 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002;23:1297-305.
47. Haefner B. NF-κB: arresting a major culprit in cancer. Drug Discov Today 2002;7:653-63.
48. Angileri FF, Aguennouz M, Conti A, et al. Nuclear factor-κB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 2008;112:2258-66.
49. Kawakami H, Tomita M, Matsuda T, et al. Transcriptional activation of survivin through the NF-κB pathway by human T-cell leukemia virus type I tax. Int J Cancer 2005;115:967-74.
50. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344:305-11.